Sutro Biopharma, Inc.
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Jane Chung
- Full Time Employees
- 128
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 111 Oyster Point Boulevard South San Francisco CA United States of America 94080
- IPO Date
- Sep 27, 2018
- CIK
- 0001382101
- Website
- sutrobio.com
- Similar Companies
- Business
- Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage oncology company, develops site-specific and novel-format antibody drug conjugates (ADCs) for cancer using its proprietary cell-free protein synthesis platforms, XpressCF and XpressCF+; core wholly owned product candidates include STRO-004, a tissue factor-targeting ADC for solid tumors such as cervical, lung and breast cancers with U.S. FDA IND clearance received in November 2025 and first-in-human dosing on track before year-end, STRO-006, a highly selective integrin beta-6 ADC for multiple solid tumors advancing toward clinical development in 2026, and a wholly owned dual-payload ADC program combining cytotoxic and immunostimulatory payloads with IND submission targeted for 2027; additional programs encompass STRO-001 targeting CD74 for multiple myeloma and non-Hodgkin lymphoma, STRO-002 (luveltamab tazevibulin) targeting folate receptor-alpha for ovarian and endometrial cancers, and STRO-003 targeting ROR1. Founded in 2003 and headquartered in South San Francisco, California, the company operates primarily in the United States with a global collaboration pipeline including partnerships with Astellas on dual-payload immunostimulatory ADCs where one program entered IND-enabling toxicology in early 2025, Ipsen on STRO-003 which Ipsen opted not to advance in 2025, Merck on cytokine derivatives, and a manufacturing partnership with VGXI for luvelta production; recent developments feature a strategic portfolio review and organizational restructuring announced in March and September 2025 prioritizing ADC programs, cessation of San Carlos manufacturing facility operations by year-end 2025, leadership transition with Jane Chung assuming CEO role from Bill Newell in March 2025 and Greg Chow appointed CFO in June 2025, entry into a research collaboration with the U.S. FDA in July 2025 to advance ADC regulatory standards, and preclinical data presentations at conferences including World ADC and SITC in November 2025 highlighting dual-payload ADCs' potential to overcome resistance.
Company News
Sutro Biopharma Appoints Lucas Donigian as Senior Vice President, Business Development
Cardio Diagnostics (NASDAQ:CDIO) & Sutro Biopharma (NASDAQ:STRO) Head-To-Head Analysis
Why is Sutro Biopharma Stock Falling On Wednesday?
Sutro Biopharma Reports Second Quarter 2026 Financial Results and Provides Early Update on STRO-004 Phase 1 Study
Here Are Friday’s Top Wall Street Analyst Research Calls: Baker Hughes, Etsy, HubSpot, Instacart, JetBlue, Roku, SpaceX, Tower Semiconductor, Trade Desk, and More
Affinity Asset Advisors LLC Grows Stock Holdings in Sutro Biopharma, Inc. $STRO
Sutro Biopharma Reports First Quarter 2026 Financial Results and Business Highlights
Here Are Thursday’s Top Wall Street Analyst Research Calls: AbbVie, Equinix, GE Healthcare, Kratos Defense, Meta Platforms, Oneok, Palantir Technologies, Wingstop, and More
Sutro Biopharma Presents Promising Preclinical Data Across its Pipeline of Next-Generation Single and Dual-Payload ADC Programs at AACR 2026
Sutro Biopharma (NASDAQ:STRO) Trading 10.4% Higher on Analyst Upgrade
Sutro Biopharma (STRO) Moves 7.4% Higher: Will This Strength Last?
Sutro Biopharma Reports Full Year 2025 Financial Results and Business Highlights
Sutro Biopharma, Inc. (NASDAQ:STRO) Receives Consensus Rating of “Hold” from Analysts
Sutro Biopharma: ADC Developer With Poor Track Record Aims For Positive 2026
Sutro Biopharma to Participate in Upcoming Investor Conferences
Sutro Biopharma (STRO) Surges 11.9%: Is This an Indication of Further Gains?
Sutro Biopharma Announces Pricing of $110.0 million Underwritten Offering
Sutro Biopharma (STRO) Soars 5.9%: Is Further Upside Left in the Stock?
Sutro Biopharma, Inc. (STRO) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Sutro Biopharma, Inc. (NASDAQ:STRO) Given Average Recommendation of “Hold” by Analysts